Cinzia Emilia Lavarino
Jefe de Grupo Senior
Research group
Cinzia Lavarino graduated in Biology in 1994 and obtained a Doctor of Biotechnology degree in 1999 from the Università degli Studi di Milano, Italy.
Between 1994 and 2001 she was trained at the Molecular Diagnostic Laboratory of the Instituto Nazionale dei Tumori in Milan.
Between 2001-2004 she completed a post-doctoral stay at the Department of Biochemistry, Faculty of Pharmacy, University of Barcelona.
In 2005, she joined the post-doctoral researcher at the Development Tumours Laboratory of the SJD Barcelona Children’s Hospital.
Since 2007 Cinzia Lavarino is Principal Investigator of the Translational Genomics group of the Laboratory of Developmental Tumours, included in the IRSJD Pediatric Cancer Program.
Since the beginning of 2019, Cinzia Lavarino has been a doctor in charge of healthcare activities (molecular diagnosis, prognosis prediction, molecular classification, identification of therapeutic targets, molecular monitoring of the disease) typical of the Molecular Oncology Laboratory of the Paediatric Cancer Center Barcelona (PCCB) of the SJD Barcelona Children's Hospital.
Professional network profiles
Last Publications
- De Bortoli M, Ivars M, Revencu N, Nassogne MC, Lavarino C, Paco-Mercader S, Lammens M, Renders A, Dumitriu D, Helaers R, Boon LM, Baselga E and Vikkula M Epilepsy with faint capillary malformation or reticulated telangiectasia associated with mosaic AKT3 pathogenic variants AMERICAN JOURNAL OF MEDICAL GENETICS PART A . : .
- Pinto EM, Fridman C, Figueiredo BC, Salvador-Hernandez H, Teixeira MR, Pinto C, Pinheiro M, Kratz CP, Lavarino C, Legal EAMF, Le A, Kelly G, Koeppe E, Stoffel EM, Breen K, Hahner S, Heinze B, Techavichit P, Krause A, Ogata T, Fujisawa Y, Walsh MF, Rana HQ, Maxwell KN, Garber JE, Rodriguez-Galindo C, Ribeiro RC and Zambetti GP Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility Human Genetics and Genomics Advances . 5(1): 100244-100244.
- Simao-Rafael M, Cruz-Martínez O, Pérez-Jaume S, Santa-María López V, Lavarino C, Salvador-Hernandez H, Muchart-Lopez J, Hinojosa J, Suñol M and Morales-La Madrid A Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center EJC Paediatric Oncology . 2: 100115.
Projects
- Project name:
- GLIOMATCH_The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
- Leader
- Andrés Morales La Madrid
- Funding entities:
- European Commission
- Code
- 101136670
- Starting - finishing date:
- 2024 - 2028
- Project name:
- Ensayo clínico de seguridad y factibilidad de inmunoterapia celular: Células dendríticas autólogas pulsadas con un lisado de líneas tumorales alogénicas, asociadas con CART anti-IL13Ra2 en pacientes con tumor difuso intrínseco de tronco (DIPG) (fase Ib)
- Leader
- Andrés Morales La Madrid
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI23/00063
- Starting - finishing date:
- 2024 - 2027
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2025
News
-
Researchers from IRSJD and IRB Barcelona unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues
A team from Institut de Recerca Sant Joan de Déu and IRB Barcelona has studied the cases of four children who have experienced two cancers during childhood and has addressed the origin of the second tumour. The work has been published in the journal Cancer Discovery.
-
New research facilities for studying children's cancer
New facilities have been opened for the children's oncology laboratory of the Institut de Recerca Sant Joan de Déu - SJD Barcelona Children's Hospital to celebrate 20 years of research. These laboratories are unique in their exclusive dedication to pediatric tumors and have over 50 researchers who focus on the study of more than ten developmental tumors.
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.